Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity
Nina Mayorek, Nili Naftali-Shani, Myriam Grunewald · 2010
Read Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity by Nina Mayorek, Nili Naftali-Shani, Myriam Grunewald (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012715.txt.
Description
Mayorek, Naftali-Shani and Grunewald tested an old pain drug against pancreatic cancer in mice. Diclofenac has been in pharmacy use for decades as an anti-inflammatory. Besides its known targets, it blocks other enzymes tied to inflammation and growth signals.
Their 2010 mouse study found the drug slowed tumour growth, partly by changing VEGF levels and arginase activity in the tumour setting. Pancreatic cancer has few working treatments, so any cheap, known drug with an effect earns attention. The work supports trials of drug reuse in this disease. The authors link both shifts to the slower growth they measured in treated mice.
Catalog record
| CREATOR | Nina Mayorek, Nili Naftali-Shani, Myriam Grunewald |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012715